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Abstract
Background: Gastrointestinal stromal tumors (GIST) constitute a large majority of mesenchymal
tumors of the gastrointestinal (GI) tract, which express the c-kit proto-oncogene protein, a cell
membrane receptor with tyrosine kinase activity. GI stromal tumors of the stomach are usually
associated with bleeding, abdominal pain or a palpable mass.
Case presentation: A 75-year-old male presented with upper abdominal pain and palpable mass.
Computed tomographic (CT) scan of the abdomen showed a large mass arising in the posterior
aspect of fundus, body, and greater curvature of the stomach. Second day after the admission, there
was significant reduction in the size of the tumor, clinically as well as radiologically. Endoscopic
biopsy showed large bulge in fundus and corpus of the stomach posteriorly with an opening in the
posterior part of the corpus, and biopsy from the edge of the opening reveled GIST. Patient
underwent curative resection.
Conclusion: Spontaneous ruptured of giant gastric stromal tumor is very rare presentation of
stomach GIST. Thorough clinical examination and timely investigation can diagnose rare
complication.
Background
Gastrointestinal stromal tumors (GIST) are the most com-
mon form of mesenchymal tumors arising from the gas-
trointestinal (GI) wall, mesentery, omentum or
retroperitoneum that express the c-kit proto-oncogene
protein [1]. This expression of c-kit distinguishes GIST
from true leiomyomas, leiomyosarcomas, and other mes-
enchymal tumors of the GI tract [1,2]. Stomach (60–70%)
and small intestine (20–30%) is the most common site
for GIST [2]. Approximately 10–30% of patients with
GIST may be asymptomatic. Stomach and small intestinal
stromal tumors are usually associated with abdominal
pain, GI bleeding or palpable mass. Around 30% of all
GISTs are malignant and liver is the most common site for
metastasis. Surgical resection is the primary treatment of
GIST [3]. The 5-year survival following curative resection
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kinase inhibitor, is the first effective drug with response
rate of 54% in the treatment of metastatic GIST. We report
here a case of GIST which presented with rupture in to the
gastric lumen.
Case presentation
A 75-year-old diabetic male presented with dull upper
abdominal pain of one-week duration. He noticed swell-
ing in left upper abdomen. There was no history of vom-
iting, fever or gastrointestinal bleeding. He had no
significant medical or family history and was non-smoker
and non-alcoholic. Physical examination showed a 14 ×
10 cm mass palpable in epigastrium and left hypochon-
drium with minimal intrinsic mobility.
Routine biochemical investigations were normal. Ultra-
sonogram and CT-scan of the abdomen showed large het-
erogeneous mass of 13 × 10 cm extending from the tail of
pancreas to anterior pararenal space, lesser sac to gastros-
plenic ligament enveloping the posterior aspect of fundus,
body and greater curvature (Figure 1). One day after the
admission, examination showed reduction in the size of
palpable mass to 8 × 6 cm size which was not associated
with aggravation of the symptoms. Ultrasonography of
the abdomen was repeated which showed reduction in
the diameter of mass to 8 × 8 cm. Upper endoscopy
showed large bulge in fundus and corpus of the stomach
posteriorly with an opening in the posterior part of the
corpus with edematous margin with dissemination of
serous fluid and necrotic material in to the stomach (Fig-
ure 2). Fluid analysis was normal for CEA and CA 19-9.
Biopsy taken from the edge of the opening showed bun-
dles of spindle cells with elongated nuclei and tumor cells
(Figure 3) and was strongly positive for CD117 immuno-
histochemical examination, diagnostic of gastrointestinal
stromal tumor (Figure 4). At laparotomy a large tumor
was seen arising from the posterior wall of stomach meas-
uring 8 × 8 cm, which has ruptured into the gastric lumen,
and was infiltrating the upper pole of spleen, anterior cap-
sule of pancreas and mesocolon. He underwent total gas-
trectomy and splenectomy with esophagojejunostomy,
and segmental transverse colectomy. Histopathology of
resected specimen showed large spindle cell GIST with >5/
50 HPF (high-power field) mitotic activity. Postoperative
period was uneventful. Postoperatively he was put on
imatinib mesylate 400 mg once daily. Patient is asympto-
matic on follow up for 11 months.
Discussion
GI stromal tumors express c-kit protein also known as CD
117, and is considered as highly specific marker that dif-
ferentiates GIST from other mesenchymal tumors such as
leiomyomas [8-10]. The majority of GISTs occur in the
stomach (60–70%) and small intestine (20–30%) [9].
GIST arises from the stomach, presented with abdominal
pain, GI bleeding or palpable mass. Around 20–30% of
GISTs detected during surgery for intestinal obstruction or
bleeding [9]. Among the diverse clinical presentation of
stomach GISTs, spontaneous ruptured in to peritoneal
cavity lead to peritonitis [11], extragastric growth [12],
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stromal tumor with cystic degeneration presenting as
hemoperitoneum [14], gastric stromal tumor with
myxoid degeneration [15] have been reported in the liter-
ature. Our patient had giant gastric GIST, which ruptured
into the stomach with dissemination of its necrotic tissue
in the stomach. There was no aggravation of the symp-
toms. Abdominal examination revealed reduction of the
size of tumor from 13 × 10 cm to 8 × 6 cm size. Ultra-
sound abdomen also confirmed 40% reduction in the size
of the tumor. Upper endoscopy biopsy from the edge of
the opening, posterior wall of the stomach was suggestive
of GIST. Since most of the GISTs are submucosal and grow
endophytically, preoperative tissue diagnosis is difficult.
In our patient biopsy from the edge of the rent and deep
inside the opening confirmed diagnosis of GIST preoper-
atively. Patient underwent complete tumor resection, with
uneventful postoperative period.
Assessment of malignant potential of a primary GIST
lesion is difficult in many cases; even as small as less than
2 cm size GIST has certain malignant potentials [9]. Cur-
rently, there is no single prognostic factor that can be used
alone to predict tumor behavior. Biological behavior of
tumor also depends on the location; for example, GISTs
arising from the small bowel or colon are generally asso-
ciated with a less favorable outcome than those arising in
the stomach [16]. Radiological and surgical factors that
have been used to determine malignancy include invasion
to adjacent organs; omental or peritoneal seeding; tumor
recurrence after surgical resection; or distant metastasis
[8,17]. Pathological factors that determine malignancy are
tumor size, mitotic activity, nuclear pleomorphism,
degree of cellularity, nuclear to cytoplasmic ratio, and
mucosal invasion [18]. Both mitotic activity and tumor
size have been identified as the most important factors
predicting malignant behavior [3,9,19]. In our patient,
most of the factors like size of the tumor, local invasion
and high mitotic activity indicated high malignant
potential.
Imatinib mesylate, competitive inhibitors of certain tyro-
sine kinases including the intracellular kinases ABL and
BCR-ABL fusion proteins present in some leukemia's, and
platelet-derived growth factor receptors [20], is the first
effective drug in the treatment of metastatic GIST. Demetri
et al [21] had reported a response rate of 54%, with
median time to response is about 13 weeks, in patients
with either inoperable or metastatic GISTs treated with a
daily dose of 400 mg or 600 me with follow-up of at least
6 months. Even in patients with large tumor, response to
imatinib mesylate can occur rapidly [22]. The optimum
dose of imatinib mesylate in the treatment of GIST is not
yet known. Toxicity increases with increasing dose, with
maximum tolerated dose was 800 mg taken for 8 weeks
[22]. Role of imatinib mesylate in the treatment of
malignant GIST after curative response is still under inves-
tigation. Rational of giving imatinib mesylate in our
patient following curative resection, was presence of a
very large tumor (>10 cm) with local invasion and high
mitotic activity (>5/50 HPF).
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Photomicrograph showing upper endoscopy biopsy specimen 
of gastric GIST showing multiple spindle cells with eosi-
nophilic cytoplasm and ovoid to elongated nuclei
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Photomicrograph of biopsy specimen with immunohisto-
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Spontaneous ruptured of giant gastric stromal tumor is
very rare presentation of stomach GIST. Clinical examina-
tion and timely investigations can diagnose this rare
complication.
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